Previous research has demonstrated an association between genetic variation in the CTRB1/2 gene and response to incretin therapies. We aimed to evaluate the role of CTRB1/2 rs7202877 (T>G) polymorphism in glycemic response to liraglutide among Greek people with T2D. 116 adults with T2D (51% female, mean BMI 35.4±6.4 kg/m2, mean age 68.3±10.9 years), who had been on treatment with liraglutide for at least 6 months were genotyped for the rs7202877 polymorphism, using real-time PCR. Responders met at least one of the following criteria: i) achievement of good glycemic control defined as HbA1c level of <7%, either at 3 or 6 months after treatment initiation, ii) reduction of the baseline HbA1c levels by ≥1% after 3 or 6 months of liraglutide use, and iii) maintenance of the optimal glucose control (HbA1c <7%) that a patient had before switching to liraglutide, after 3 or 6 months of treatment. Patients who failed to fulfil any of those criteria, were characterized as non-responders. 81 (70%) patients were classified as responders and 35 (30%) as non-responders. 97 (84%) patients were homozygous for the wild type T allele (TT) and 19 (16%) patients carried one polymorphic G allele (TG). Heterozygotes tended to have better response to liraglutide treatment; still, the difference was not significant (OR: 1.25, 95% CI: 0.4, 3.8, P=0.69). The probability of being a responder was 45% greater, when the baseline HbA1c was increased by 1% (adjusted for gender and baseline weight OR: 1.45, 95% CI: 1.05, 2.1, P=0.048). Additionally, an increase in baseline weight by 10 kg was associated with 26% reduced probability of being a responder (adjusted for gender and baseline HbA1c OR: 0.97, 95% CI: 0.94, 0.99, P=0.011). Our findings do not suggest a role of CTRB1/2 rs7202877 in affecting glycemic response to liraglutide. Lower baseline body weight and higher baseline glycemia might be related to better glycemic control following treatment with liraglutide.


A. Kyriakidou: None. A.V. Kyriazou: Research Support; Self; Novo Nordisk A/S. T. Koufakis: None. Y. Vasilopoulos: None. I. Avramidis: None. S. Baltagiannis: None. E. Manthou: None. D.G. Goulis: None. P. Zebekakis: None. K. Kotsa: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Sanofi-Aventis, Takeda Pharmaceutical Company Limited. Speaker’s Bureau; Self; Menarini Group. Other Relationship; Self; Novo Nordisk Inc.


Novo Nordisk (91220)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at